India has approved BPaLM regimen for Multidrug Resistant Tuberculosis (MDR-TB) treatment recently.

As part of India’s commitment to eliminate TB, five years ahead of the global target by 2025, this step has become crucial.

BPaLM regimen includes new drug Pretomanid with Bedaquiline, Linezolid, and Moxifloxacin. It was proven safer, more effective, and quicker than previous treatments.

This regimen cures drug-resistant TB in 6 months vs. traditional 20-month treatments. Almost 75,000 MDR-TB patients benefit from shorter regimen.

It is a cost-effective solution validated by subject experts and Health Technology Assessment

Nationwide roll-out plan being prepared by Central TB Division, Including capacity building for health professionals

This move is expected to significantly boost India's progress towards TB elimination goal.

Read complete article - Click here